Erika Hammarlund1, Archana Thomas1, Elizabeth A Poore2, Ian J Amanna2, Abby E Rynko1, Motomi Mori3,4, Zunqiu Chen4, Mark K Slifka1. 1. Division of Neuroscience, Oregon National Primate Research Center, Department of Molecular Microbiology and Immunology, Oregon Health & Science University. 2. Najít Technologies,Beaverton. 3. Biostatistics Shared Resource, Knight Cancer Institute. 4. Division of Biostatistics, Department of Public Health & Preventive Medicine, Oregon Health & Science University, Portland.
Abstract
BACKGROUND: Many adult immunization schedules recommend that tetanus and diphtheria vaccination be performed every 10 years. In light of current epidemiological trends of disease incidence and rates of vaccine-associated adverse events, the 10-year revaccination schedule has come into question. METHODS: We performed cross-sectional analysis of serum antibody titers in 546 adult subjects stratified by age or sex. All serological results were converted to international units after calibration with international serum standards. RESULTS: Approximately 97% of the population was seropositive to tetanus and diphtheria as defined by a protective serum antibody titer of ≥0.01 IU/mL. Mean antibody titers were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively. Antibody responses to tetanus declined with an estimated half-life of 14 years (95% confidence interval, 11-17 years), whereas antibody responses to diphtheria were more long-lived and declined with an estimated half-life of 27 years (18-51 years). Mathematical models combining antibody magnitude and duration predict that 95% of the population will remain protected against tetanus and diphtheria for ≥30 years without requiring further booster vaccination. CONCLUSIONS: These studies demonstrate that durable levels of protective antitoxin immunity exist in the majority of vaccinated individuals. Together, this suggests that it may no longer be necessary to administer booster vaccinations every 10 years and that the current adult vaccination schedule for tetanus and diphtheria should be revisited.
BACKGROUND: Many adult immunization schedules recommend that tetanus and diphtheria vaccination be performed every 10 years. In light of current epidemiological trends of disease incidence and rates of vaccine-associated adverse events, the 10-year revaccination schedule has come into question. METHODS: We performed cross-sectional analysis of serum antibody titers in 546 adult subjects stratified by age or sex. All serological results were converted to international units after calibration with international serum standards. RESULTS: Approximately 97% of the population was seropositive to tetanus and diphtheria as defined by a protective serum antibody titer of ≥0.01 IU/mL. Mean antibody titers were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively. Antibody responses to tetanus declined with an estimated half-life of 14 years (95% confidence interval, 11-17 years), whereas antibody responses to diphtheria were more long-lived and declined with an estimated half-life of 27 years (18-51 years). Mathematical models combining antibody magnitude and duration predict that 95% of the population will remain protected against tetanus and diphtheria for ≥30 years without requiring further booster vaccination. CONCLUSIONS: These studies demonstrate that durable levels of protective antitoxin immunity exist in the majority of vaccinated individuals. Together, this suggests that it may no longer be necessary to administer booster vaccinations every 10 years and that the current adult vaccination schedule for tetanus and diphtheria should be revisited.
Authors: S Dittmann; M Wharton; C Vitek; M Ciotti; A Galazka; S Guichard; I Hardy; U Kartoglu; S Koyama; J Kreysler; B Martin; D Mercer; T Rønne; C Roure; R Steinglass; P Strebel; R Sutter; M Trostle Journal: J Infect Dis Date: 2000-02 Impact factor: 5.226
Authors: Karen S Wagner; Joanne M White; Nick J Andrews; Ray Borrow; Elaine Stanford; Emma Newton; Richard G Pebody Journal: Vaccine Date: 2012-09-26 Impact factor: 3.641
Authors: Lori Garman; Amanda J Vineyard; Sherry R Crowe; John B Harley; Christina E Spooner; Limone C Collins; Michael R Nelson; Renata J M Engler; Judith A James Journal: Vaccine Date: 2014-08-17 Impact factor: 3.641
Authors: Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; Carolyn B Bridges; David K Kim; Tamara Pilishvili; Craig M Hales; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2015-02-06 Impact factor: 17.586
Authors: C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio Journal: Clin Exp Immunol Date: 2018-09-20 Impact factor: 4.330
Authors: Freddy Caldera; Sumona Saha; Arnold Wald; Christine A Garmoe; Sue McCrone; Bryant Megna; Dana Ley; Mark Reichelderfer; Mary S Hayney Journal: Dig Dis Sci Date: 2018-03-29 Impact factor: 3.199
Authors: Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio Journal: Biomedicines Date: 2022-08-22
Authors: M Borella-Venturini; C Frasson; F Paluan; D DE Nuzzo; G DI Masi; M Giraldo; F Chiara; A Trevisan Journal: Epidemiol Infect Date: 2017-03-15 Impact factor: 4.434
Authors: Alice Antia; Hasan Ahmed; Andreas Handel; Nichole E Carlson; Ian J Amanna; Rustom Antia; Mark Slifka Journal: PLoS Biol Date: 2018-08-10 Impact factor: 8.029
Authors: Archana Thomas; Erika Hammarlund; Lina Gao; Susan Holman; Katherine G Michel; Marshall Glesby; Maria C Villacres; Elizabeth T Golub; Nadia R Roan; Audrey L French; Michael H Augenbraun; Mark K Slifka Journal: J Infect Dis Date: 2020-06-29 Impact factor: 7.759